Noxopharm Announces Novel mRNA Vaccine Enhancer

28 March 2023 | Tuesday | News


Innovative biotech company Noxopharm Limited (ASX:NOX) announces the development of a new proprietary product candidate based on mRNA technology as part of the company’s SofraTM preclinical platform.
SOF-VACTM blocks inflammation receptors, thereby blocking inflammation and reducing vaccine side effects.

SOF-VACTM blocks inflammation receptors, thereby blocking inflammation and reducing vaccine side effects.

  • Proprietary SOF-VACTM asset with potential to make mRNA vaccines safer, better tolerated by patients and more cost-effective to manufacture
  • Preclinical first-in-class mRNA technology based on company’s SofraTM platform
  • Smallest molecule of its type to have demonstrated strong activity against inflammation
  • Developed in collaboration with strategic partner Hudson Institute of Medical Research
  • Growing worldwide activity in multi-billion mRNA market

A lead candidate has now been selected for further development. Under the ongoing collaboration with the Hudson Institute of Medical Research, the team has synthesised a novel ‘vaccine enhancer’ called SOF-VACTM.


This preclinical technology aims to make a broad range of mRNA vaccines safer by reducing inflammation associated with mRNA vaccines. In addition, the technology has the potential to support more cost-effective mRNA vaccine manufacturing.

 

The team’s recent development work on SOF-VACTM has shown strong in vitro and in vivo activity against inflammation. SOF-VACTM represents a first-in-class achievement as the smallest known molecule of its type to have demonstrated this activity. The major advantage of such a small molecule is it reduces the risk of off-target effects compared to larger molecules of this type.

 

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close